Jesús S. M.
- Country
- Spain
- Department
- Hematology
Research Overview
- Phase 1b Evaluation of Subcutaneous Daratumumab with Bispecific T Cell Redirection Antibodies in Multiple Myeloma Patients
- Phase III Randomized Trial of Bortezomib, Melphalan, Prednisone, Lenalidomide, Dexamethasone, Carfilzomib, and Daratumumab in Elderly Patients with Newly Diagnosed Multiple Myeloma
- Phase II Multicenter Study of Carfilzomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma Patients ≤70 Years
Data & Insights
Has run more than one trial at 25 of 101 partner sites.
Specializations
Multiple Myeloma Treatment
This investigator specializes in the treatment of multiple myeloma, with particular emphasis on developing innovative therapies for both newly diagnosed and relapsed/refractory cases.
- Relapsed and Refractory Multiple Myeloma (RRMM)
- Newly Diagnosed Multiple Myeloma (NDMM)
- High-Risk Smoldering Multiple Myeloma
The research encompasses various treatment approaches for different patient populations, including elderly patients and those ineligible for transplantation.
Novel Therapeutic Approaches
The investigator focuses on evaluating cutting-edge treatment modalities including targeted antibody therapies and cellular therapies.
- Bispecific T Cell Redirection Antibodies
- BCMA-Targeted Therapies
- Subcutaneous Treatment Administration
Research includes investigation of combination therapies and novel drug delivery methods to improve treatment outcomes.
Disease Monitoring and Response
The investigator's work includes assessment of treatment response and disease progression using advanced monitoring techniques.
- Minimal Residual Disease Assessment
- Immunophenotypic Response Evaluation
- Progression-Free Survival Monitoring
Focus extends to early intervention strategies in high-risk precursor conditions to prevent disease progression.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.